Affibody and Astra Tech enter into license and research agreement
The scope is development of devices for safe blood management
17-Sep-2004 -
Affibody will develop Affibody® molecules targeting blood components for removal of harmful proteins from patients' blood. Affibody will receive research funding during three years, milestone payments and royalty on worldwide sales of products developed under the collaboration.
Astra Tech ...
ligands
milestone payments
proteins
+2